Are cracks in the “war on drugs” facade… starting to form/show ?

See the source image

Could things in the war on drugs’ facade starting to show cracks ?  There has been a few things coming to the front that may suggest that may be the case…

I have made several posts over the past couple of weeks that I have not seen before

The “NO WIN GAME” … damn if you do… damn if you don’t

we know that it is normal for the DEA to come after a prescriber when a pt OD’s on opiates.. it is as if a prescriber never has a pt die… never has one that commits suicide… and that all opiate OD’s are “accidental “?  I have had untold number of chronic pain pts that have told me that they have contacted numerous law firms about suing for denial of care, ADA violations, pt abuse, medical battery and the like and have yet to find a law firm that is interested in their case.

The above article about a prescriber is being sued for a pt’s suicide – no doubt it was a suicide because the pt used a GUN… the prescriber had been weaning the pt off of his opiates for about one month and had promised to continue assistance in weaning for another month.. when the pt chose the ultimate solution to end his pain.

Yet a law firm is apparently ready, willing and able to sue this prescriber on behalf of the pt’s spouse because of the pt’s suicide.  Is this lawsuit just an anomaly or the first in many that may come to bear on prescribers for various reasons in failing to properly treat – or not treat at all – chronic pain pts.. especially those suffering from intractable moderate/severe chronic pain and have a medical necessity for 24/7 opiate therapy ?


if I approve too many expensive drugs, I won’t get my bonus at the end of the month.

This is story about a number of medical directors for various insurance companies who stated that they routinely deny coverage of care because they didn’t want to lose their monthly bonus. Who believes that a for-profit health insurance company really has the pt’s health/quality of life as a primary focus of the reason that they are in business ?


medical director insurer admitted he never looked at patients’ records when deciding whether to approve or deny care.

Does anyone believe that this one medical director from Aetna is a OUTLIER  or just the first one that was under oath in a court of law… and the doctor’s “reasoning” was that “he was following Aetna’s training, in which nurses reviewed records and made recommendations to him.”  So it would appear the Aetna is basically  granting nurses both diagnostic and prescriptive authority.  The term “nurse” can cover a whole range of educational background… from a 1 yr LPN, 2 yr RN, 4 yr BSRN, ARNP, PA, NP.  What if those nurses have the same monthly bonus incentive as those medical directors in the previous article ?  CVS Health is in the process of buying Aetna for some 60 + BILLION…  it would appear that the profitability of Aetna is quite sizeable…


Are we going from a covert GENOCIDE to CARPETING BOMBING the chronic pain community ?

We are seeing entities (PBM) Prescription benefit managers that are dictating how much or little opiate therapy a pt can have… the letter in this posts demonstrates that CVS is demanding that this particular pt reduce the pt’s Methadone from 70 mg/day to 24 mg/day and eliminate the 20 mg Oxycodone 4xd as needed for breakthru.  This is the therapy that this pt has been on for numerous years and according to the date on this letter the pt was being granted 60-90 days to wean down to what CVS considered a therapeutic level for this particular pt.  “to help ensure the pt’s use of opiates for pain management is SAFE “

now if this pt has been taking this amount of opiates for years… the pt is – without a question – opiate dependent and since the pt has not experienced any adverse reaction to this dosing level.. for this particular pt… it should be considered SAFE


how many more cracks in this war on drugs facade will we see over the near future and how much longer are law firms going to stand on the side lines and turn a blind eye to what is happening to not only chronic pain pts, but all too many pts with chronic diseases ?

#Kolodny suggesting that Purdue will continue to be blamed for the opiate crisis long after they stop promoting opiates ?

Opioid Maker To Stop Marketing Painkillers to Docs

https://www.webmd.com/mental-health/addiction/news/20180212/opioid-maker-to-stop-marketing-painkillers-to-docs

Faced with lawsuits and blame for contributing to the United States’ opioid epidemic, OxyContin maker Purdue Pharma announced that it will stop promoting its opioid painkiller drugs to doctors.

The company is slashing its sales force in half to 200, and the remaining representatives will no longer visit doctors to market Purdue’s opioid products, the Los Angeles Times reported.

“We have restructured and significantly reduced our commercial operation and will no longer be promoting opioids to prescribers,” according to a company statement. “Going forward, questions and requests for information about our opioid products will be handled through direct communications with our medical affairs department.”

The announcement was welcomed by Brandeis University researcher Dr. Andrew Kolodny, but, “It’s pretty late in the game to have a major impact,” he told the Times.

“The genie is already out of the bottle,” said Kolodny, executive director and co-founder of Physicians for Responsible Opioid Prescribing.

“Millions of Americans are now opioid-addicted because the campaign that Purdue and other opioid manufacturers used to increase prescribing worked well. And as the prescribing went up, it led to a severe epidemic of opioid addiction,” Kolodny told the Times.

Purdue faces dozens of lawsuits from U.S. cities that want to hold the company financially responsible for the opioid epidemic.

A Times investigation found that Purdue had significant evidence that its opioid pills were being illegally trafficked but often did not share it with local law enforcement agencies or halt supplies of the drugs.

It’s estimated that more than 7 million Americans have abused OxyContin since it became available in the U.S. in 1996, the Times reported.

It’s not clear if other opioid painkiller makers will also stop marketing the drugs to doctors, Kolodny noted.

 

“We would have more success in encouraging cautious prescribing if drug companies stopped promoting aggressive prescribing,” he told the Times.

Another questions is whether Purdue will continue marketing opioid painkillers to doctors outside the U.S. through its international arm.

 

medical director insurer admitted he never looked at patients’ records when deciding whether to approve or deny care.

CNN Exclusive: California launches investigation following stunning admission by Aetna medical director

http://www.cnn.com/2018/02/11/health/aetna-california-investigation/index.html

(CNN)California’s insurance commissioner has launched an investigation into Aetna after learning a former medical director for the insurer admitted under oath he never looked at patients’ records when deciding whether to approve or deny care.

California Insurance Commissioner Dave Jones expressed outrage after CNN showed him a transcript of the testimony and said his office is looking into how widespread the practice is within Aetna.
“If the health insurer is making decisions to deny coverage without a physician actually ever reviewing medical records, that’s of significant concern to me as insurance commissioner in California — and potentially a violation of law,” he said.
Aetna, the nation’s third-largest insurance provider with 23.1 million customers, told CNN it looked forward to “explaining our clinical review process” to the commissioner.

California insurance commissioner Dave Jones launched the investigation after being contacted by CNN.

The California probe centers on a deposition by Dr. Jay Ken Iinuma, who served as medical director for Aetna for Southern California from March 2012 to February 2015, according to the insurer.
During the deposition, the doctor said he was following Aetna’s training, in which nurses reviewed records and made recommendations to him.
Jones said his expectation would be “that physicians would be reviewing treatment authorization requests,” and that it’s troubling that “during the entire course of time he was employed at Aetna, he never once looked at patients’ medical records himself.”
“It’s hard to imagine that in that entire course in time, there weren’t any cases in which a decision about the denial of coverage ought to have been made by someone trained as a physician, as opposed to some other licensed professional,” Jones told CNN.
“That’s why we’ve contacted Aetna and asked that they provide us information about how they are making these claims decisions and why we’ve opened this investigation.”
The insurance commissioner said Californians who believe they may have been adversely affected by Aetna’s decisions should contact his office.
Members of the medical community expressed similar shock, saying Iinuma’s deposition leads to questions about Aetna’s practices across the country.
“Oh my God. Are you serious? That is incredible,” said Dr. Anne-Marie Irani when told of the medical director’s testimony. Irani is a professor of pediatrics and internal medicine at the Children’s Hospital of Richmond at VCU and a former member of the American Board of Allergy and Immunology’s board of directors.
“This is potentially a huge, huge story and quite frankly may reshape how insurance functions,” said Dr. Andrew Murphy, who, like Irani, is a renowned fellow of the American Academy of Allergy, Asthma and Immunology. He recently served on the academy’s board of directors.

The Gillen Washington case

Gillen Washington, 23, says he hopes to force change at Aetna.

The deposition by Aetna’s former medical director came as part of a lawsuit filed against Aetna by a college student who suffers from a rare immune disorder. The case is expected to go to trial later this week in California Superior Court.
Gillen Washington, 23, is suing Aetna for breach of contract and bad faith, saying he was denied coverage for an infusion of intravenous immunoglobulin (IVIG) when he was 19. His suit alleges Aetna’s “reckless withholding of benefits almost killed him.”
Aetna has rejected the allegations, saying Washington failed to comply with their requests for blood work. Washington, who was diagnosed with common variable immunodeficiency, or CVID, in high school, became a new Aetna patient in January 2014 after being insured by Kaiser.
Aetna initially paid for his treatments after each infusion, which can cost up to $20,000. But when Washington’s clinic asked Aetna to pre-authorize a November 2014 infusion, Aetna says it was obligated to review his medical record. That’s when it saw his last blood work had been done three years earlier for Kaiser.
Despite being told by his own doctor’s office that he needed to come in for new blood work, Washington failed to do so for several months until he got so sick he ended up in the hospital with a collapsed lung.
Once his blood was tested, Aetna resumed covering his infusions and pre-certified him for a year. Despite that, according to Aetna, Washington continued to miss infusions.
Washington’s suit counters that Aetna ignored his treating physician, who appealed on his behalf months before his hospitalization that the treatment was medically necessary “to prevent acute and long-term problems.”
“Aetna is blaming me for what happened,” Washington told CNN. “I’ll just be honest, it’s infuriating to me. I want Aetna to be made to change.”
During his videotaped deposition in October 2016, Iinuma — who signed the pre-authorization denial — said he never read Washington’s medical records and knew next to nothing about his disorder.

Intravenous immunoglobulin can cost as much as $20,000 per treatment. It helps patients like Gillen Washington stave off infection.

 
Questioned about Washington’s condition, Iinuma said he wasn’t sure what the drug of choice would be for people who suffer from his condition.
Iinuma further says he’s not sure what the symptoms are for the disorder or what might happen if treatment is suddenly stopped for a patient.
“Do I know what happens?” the doctor said. “Again, I’m not sure. … I don’t treat it.”
Iinuma said he never looked at a patient’s medical records while at Aetna. He says that was Aetna protocol and that he based his decision off “pertinent information” provided to him by a nurse.
“Did you ever look at medical records?” Scott Glovsky, Washington’s attorney, asked Iinuma in the deposition.
“No, I did not,” the doctor says, shaking his head.
“So as part of your custom and practice in making decisions, you would rely on what the nurse had prepared for you?” Glovsky asks.
“Correct.”
Iinuma said nearly all of his work was conducted online. Once in a while, he said, he might place a phone call to the nurse for more details.
How many times might he call a nurse over the course of a month?
“Zero to one,” he said.
Glovsky told CNN he had “never heard such explosive testimony in two decades of deposing insurance company review doctors.”

Aetna’s response

Aetna defended Iinuma, who is no longer with the company, saying in its legal brief that he relied on his “years of experience” as a trained physician in making his decision about Washington’s treatment and that he was following Aetna’s Clinical Policy Bulletin appropriately.
“Dr. Iinuma’s decision was correct,” Aetna said in court papers. “Plaintiff has asserted throughout this litigation that Dr. Iinuma had no medical basis for his decision that 2011 lab tests were outdated and that Dr. Iinuma’s decision was incorrect. Plaintiff is wrong on both counts.”

Gillen Washington receives an infusion of the medicine needed to boost his immune system. He calls it "the magic juice."

In its trial brief, Aetna said: “Given that Aetna does not directly provide medical care to its members, Aetna needs to obtain medical records from members and their doctors to evaluate whether services are ‘medically necessary.’ Aetna employs nurses to gather the medical records and coordinate with the offices of treating physicians, and Aetna employs doctors to make the actual coverage-related determinations.
“In addition to applying their clinical judgment, the Aetna doctors and nurses use Aetna’s Clinical Policy Bulletins (‘CPBs’) to determine what medical records to request, and whether those records satisfy medical necessity criteria to support coverage. These CPBs reflect the current standard of care in the medical community. They are frequently updated, and are publicly available for any treating physician to review.”
Jones, the California insurance commissioner, said he couldn’t comment specifically on Washington’s case, but what drew his interest was the medical director’s admission of not looking at patients’ medical records.
“What I’m responding to is the portion of his deposition transcript in which he said as the medical director, he wasn’t actually reviewing medical records,” Jones told CNN.
He said his investigation will review every individual denial of coverage or pre-authorization during the medical director’s tenure to determine “whether it was appropriate or not for that decision to be made by someone other than a physician.”
If the probe determines that violations occurred, he said, California insurance code sets monetary penalties for each individual violation.
CNN has made numerous phone calls to Iinuma’s office for comment but has not heard back. Heather Richardson, an attorney representing Aetna, declined to answer any questions.
Asked about the California investigation, Aetna gave this written statement to CNN:
“We have yet to hear from Commissioner Jones but look forward to explaining our clinical review process.
“Aetna medical directors are trained to review all available medical information — including medical records — to make an informed decision. As part of our review process, medical directors are provided all submitted medical records, and also receive a case synopsis and review performed by a nurse.
“Medical directors — and all of our clinicians — take their duties and responsibilities as medical professionals incredibly seriously. Similar to most other clinical environments, our medical directors work collaboratively with our nurses who are involved in these cases and factor in their input as part of the decision-making process.”

Gillen Washington became emaciated and gravely ill after four months without treatment.

‘A huge admission’

Dr. Arthur Caplan, founding director of the division of medical ethics at New York University Langone Medical Center, described Iinuma’s testimony as “a huge admission of fundamental immorality.”
“People desperate for care expect at least a fair review by the payer. This reeks of indifference to patients,” Caplan said, adding the testimony shows there “needs to be more transparency and accountability” from private, for-profit insurers in making these decisions.
Murphy, the former American Academy of Allergy Asthma and Immunology board member, said he was “shocked” and “flabbergasted” by the medical director’s admission.
“This is something that all of us have long suspected, but to actually have an Aetna medical director admit he hasn’t even looked at medical records, that’s not good,” said Murphy, who runs an allergy and immunology practice west of Philadelphia.
“If he has not looked at medical records or engaged the prescribing physician in a conversation — and decisions were made without that input — then yeah, you’d have to question every single case he reviewed.”
Murphy said when he and other doctors seek a much-needed treatment for a patient, they expect the medical director of an insurance company to have considered every possible factor when deciding on the best option for care.
Follow CNN Health on Facebook and Twitter

See the latest news and share your comments with CNN Health on Facebook and Twitter.

“We run into the prior authorization issues when we are renewing therapy, when the patient’s insurance changes or when an insurance company changes requirements,” he said.
“Dealing with these denials is very time consuming. A great deal of nursing time is spent filling and refilling out paperwork trying to get the patient treatment.
“If that does not work, then physicians need to get involved and demand medical director involvement, which may or may not occur in a timely fashion — or sometimes not at all,” he said. “It’s very frustrating.”
 

The “NO WIN GAME” … damn if you do… damn if you don’t

From the prescriber

Sued by widow of patient who committed suicide 12/19,

He has been tapering for months.

Successfully came off fentanyl. 

No one else in the state would prescribe for him. 

After Dr xxxxx was convicted ,

I notified my remaining 8-9 patients on opiates that I could no longer do this for them. 

Gave them notice,

Promised to help for two more months as I retire from practice, due to the hostile regulatory environment. 

pt was initially sanguine,

But a few days before his death got very suicidal, his son wrestled a gun away,

Was placed on a hold,

Then released. 

He cancelled an appointment with me Sunday

Died by Tuesday, self inflicted gsw. 

So awful. 

Now 

Sued for NOT treating a patient

 

 

 

 

 

Apparently some family members of pts that are being weaned from their opiates and things go “sideways” for the pt’s outcome have found attorneys that will sue for a prescriber stopping to prescribe opiates for a opiate dependent pt with chronic pain.

 

maybe it is time for prescribers to start having as much or more fear of the pt’s and/or their survivors when they are taken and/or weaned off their opiates ?

Are we going from a covert GENOCIDE to CARPETING BOMBING the chronic pain community ?

The above 2 page letter was received by one of those unfortunate intractable chronic pain pt has CVS Health/Caremark as their PBM.  This pt has been on 70 mg of Methadone/day and 20 mg Oxycodone 3xd as needed for some time. According to CVS this pt needs to be at abt 25 mg/day of Methadone to help assure that the pt’s use of opiates is safe.  IMO .. one of the basics of the practice of medicine is the starting, changing, stopping a pt’s therapy … I am pretty sure that a corporation cannot obtain a medical degree nor pass the medical licensing board.. So who within CVS is attempting to practice medicine ?

They have a Chief Medical Director Dr. Troyen Brennan… so one could presume that anything dealing with a pt’s medication would have to be signed off by the CHIEF MEDICAL DIRECTOR recently did a post about CVS and Dr Brennan  CVS Pharmacy Will Limit Prescriptions for Opioids

This post is a “little long” .. .but goes into some detail about how – IMO – pts need to deal with this “practicing medicine with a license”.

Many public corporations seem to function under the premise that “nothing is illegal… until they get caught..”  If you doubt this, just look at all the lawsuits and fines involving large corporations.

Those in the chronic pain can continue to “sit on their hands” … try to keep “their heads low enough to stay off the radar”…but… there are entities out there that are for all intensive purposes are intending to CARPET BOMB the chronic pain community.

 

 

 

 

 

 

 

 

 

 

 

 

 

High opiate doses may be clinically appropriate… the bureaucracy finds it politically unacceptable ?

Are Pharmacy Benefit Managers Screwing Us All? | Incident Report 055

External Reasons Pharmacists Feel Burned Out

https://www.doximity.com/doc_news/v2/entries/11034750

I spoke with a pharmacist the other day who told me her job was messing up her life.

Her favorite pharmacy tech was being transferred to another location, and she was convinced that her manager didn’t understand the implications for her or the pharmacy.

Pharmacists, especially those in a retail setting, are feeling the pressure. Burnout is happening at higher and higher rates and the result is low productivity and high turnover. Pharmacists in any community setting will confirm they are incredibly busy, extremely distracted, and they often don’t have time to take a break or even use the bathroom. The long-term result is a loss of talent.

In the face of these circumstances, some businesses callously suggest that the pharmacists themselves carry the blame for burnout because they don’t handle pressure well.

To me, that thought is appalling. I would argue that if you put any pharmacist in a community store with a requirement to fill more than 400 prescriptions a day with the help of only one pharmacy tech, over the span of 5, 10, 20, or 30 years, you will create a burned-out pharmacist.

It’s worth mentioning, too, that these pharmacists successfully completed the PharmD degree, which requires 4 years of stressful professional work in addition to the undergraduate requirements. It’s a huge accomplishment, and that level of perseverance suggests that working in a pharmacy should be no problem for pharmacists.

Unfortunately, I would argue that it’s the work environment that has created burnout in more than 50% of practicing pharmacists. There are exceptions to this, of course, but it isn’t a certain niche of pharmacy that is experiencing the burnout. It’s the profession as a whole.

  1. Distractions

Beth Lofgren wrote a piece for Pharmacy Times about how many times she was distracted in a single day while working in a hospital setting. She recorded more than 150 distractions in one day, including ringing phones, personal conversations, busy doorways, background music, and out-of-stock medications.

In fact, a University of California study found that it takes workers an average of 25 minutes to return to an original task after distraction.

Unfortunately, pharmacists are barraged with distractions. Within the health care industry, they may have the most distracting job of all. The danger, of course, is that distraction can cause fatigue, and fatigue can reduce efficiency, resulting in a failure to complete all the day’s requirements.

  1. Constant Multitasking

Think of multitasking as a single drop of water falling on a rock. One drop of water will leave no visible marks on the stone, but hundreds of drops a week will eventually wear a hole in the rock. In the same way, multiple distractions in a day lead to decision fatigue: a deteriorating quality of decisions that results from long sessions of decision-making. In the wake of such fatigue, simple decisions such as what to eat for dinner become overwhelming.

David Meyer, in a University of Michigan study, found that switching tasks midstream increases the time required to finish both tasks by 25%.

Furthermore, a study in England revealed that task-switching in pharmacies can lead to dispensing errors, which affects both pharmacist and patient.

The multitasking problem is a system issue rather than a personal issue, and it leads to pharmacist burnout.

  1. High Demands and Insufficient Time

Pharmacists constantly tell me they are being asked to do more work with fewer resources. Stated another way, they don’t know how to meet their managers’ demands because they haven’t been given the means to do so.

Pharmacists have extremely high demands on their time and their decisions. The priorities in one day often exceed the time needed to complete them, so sometimes high-priority tasks are neglected for lower-priority tasks. The result could mean compromised patient care.

  1. Lack of Training

Pharmacists on the front lines are often told what to do by management without being given a viable plan of action. One pharmacist told me she had more cases than she could humanly handle within one day. With no plan of action, it was impossible to do all that was required of her.

As a result, she was constantly behind in her work and fearful of losing her job.

  1. Lack of Connection to Company

I’ve never met a single pharmacist who absolutely loved his company: a pharmacist who was able to state the company’s vision statement and core values. I know they exist, but there aren’t many of them.

Pharmacists who don’t feel connected to their company often feel alienated from the company’s larger purpose. They aren’t able to identify with the company’s larger, altruistic mission and they aren’t able to see how they fit within that purpose. Without that purpose for their job, they feel distant, which ultimately leads to a negative company culture.

What Burnout Feels Like

Can you blame pharmacists for being negative at work? There are numerous demands on their time and countless ways for them to feel as though they are failing. They feel naturally pessimistic. They are frequently yelled at by patients, doctors, nurses, and managers. They never win and they never feel as though they can get ahead. Pharmacists are victim to an endless raid on their attention and ultimately, they feel trapped.

Independent pharmacists .. the pt is their BOSS… they don’t have a whole ladder of supervisors and management… they also do have all the expensive of supporting all of that infrastructure.  Most will instead invest in ancillary staffing and the best ancillary automation… all  of that means is that they are able to provide better customer service both in regards to prompt and personal service.

Here is a website that can help you locate a independent by zip code http://www.ncpanet.org/home/find-your-local-pharmacy

most accept most insurances and your out of pocket copays are generally the same, and on top of that… these locally owned stores all the money stays in YOUR COMMUNITY.

 

 

Scientists Blast FDA, Warn That a Ban on Kratom Would Cause More Opioid Deaths

https://www.blacklistednews.com/article/63664/scientists-blast-fda-warn-that-a-ban-on-kratom-would-cause-more-opioid.html

The United States Food and Drug Administration ramped up its “War on Kratom” this week by labeling the natural herb as an opioid, and a group of scientists is stepping up to vouch for kratom’s safety, and to argue that banning it would only lead to more opioid-related deaths.

In a statement, FDA Commissioner Scott Gottlieb warned that there is “even stronger evidence of kratom compounds’ opioid properties.” He claimed that there is evidence of 36 deaths related to kratom, but that “many of the cases received could not be fully assessed because of limited information provided.”

In response, a group of scientists came together to send a letter to the acting administrator of the Drug Enforcement Administration, Robert Patterson; and the counselor to the president who is overseeing the administration’s response to the opioid crisis, Kellyanne Conway.

The letter strongly criticized the FDA’s recommendation to label kratom as a Schedule I drug, which would mean that the government will claim that it has no medicinal value.

“We believe strongly that the current body of credible research on the actual effects of kratom demonstrates that it is not dangerously addictive, nor is it similar to ‘narcotics like opioids’ with respect to ‘addiction’ and ‘death’ as stated by the FDA in its November 14th Kratom Advisory. Equally important, four surveys indicate that kratom is presently serving as a lifeline away from strong, often dangerous opioids for many of the several million Americans who use kratom. A ban on kratom that would be imposed by CSA Scheduling would put them at risk of relapse to opioid use with the potential consequence of overdose death. Similar unintended consequences are to be expected in some who would be forced to use opioids to manage acute or chronic pain.”

The scientists noted that when kratom is consumed in raw plant form, “it does not appear to produce the highly addictive euphoria or lethal respiratory depressing effects of classical opioids.” In fact, they argued that labeling kratom as a Schedule I drug would actually increase the number of opioid-related deaths in the United States.

“It is our collective judgment that placing kratom into Schedule I will potentially increase the number of deaths of Americans caused by opioids because many people who have found kratom to be their lifeline away from strong opioids will be vulnerable to resumption of that opioid use, whether their prior opioid use was for relief of pain or due to opioid addiction,” the scientists wrote.

The letter cited several national surveys and a wealth of studies from both the U.S. and Asia, which found that “kratom has been used as a safer alternative to opioids for more than a century,” and if the government truly cared about the safety of the consumer, they would refrain from making kratom a Schedule I drug.

Although the FDA is claiming that kratom is responsible for at least 44 deaths, that is nothing when compared to the number of deaths that have occurred from opioid overdoses in recent years. As President Trump noted at his first State of the Union address, “In 2016, we lost 64,000 Americans to drug overdoses: 174 deaths per day. Seven per hour.”

However, the scientists questioned whether the FDA could actually prove that the deaths it cited were related to kratom overdoses. They noted that while opioid overdose deaths result from respiratory depression and death at high doses, the deaths the FDA claims are from kratom overdoses include “a wide variety of apparent causes in people suffering from various diseases and/or taking other substances that also likely contributed to their deaths.”

Why is the FDA pushing to ban kratom when research has shown that not only is it a safer alternative to opioids, but that it actually helps to prevent opioid-overdose deaths?

As The Free Thought Project has reported, by pushing for a ban on kratom, the FDA is ensuring that Big Pharma will have a lifetime of profit, and the commissioner of the FDA is directly responsible:

Before taking over the FDA and using his position to enrich his fellow legal drug dealers, Gottlieb was a member of GlaxoSmithKline’s product investment board. And, as TFTP has previously reported GlaxoSmithKline owns a patent on a kratom alkaloid designed for the very purpose of treating pain, thereby alleviating dependency on opioids. One of Kratom’s alkaloids—Speciofoline—was researched decades ago by Gottlieb’s former employer and its effects have been widely studied and reported on.

It just so happens that a patent was filed for Speciofoline on August 10, 1964. The patent claims the “alkaloid has useful pharmacodynamic activity, particularly analgetic and antitussive activity.” But that’s not all. Other studies—which the FDA says do not exist—have been conducted for the specific task of treating opioid dependency.

Many people take dangerously high amounts of ibuprofen

http://www.foxnews.com/health/2018/02/08/many-people-take-dangerously-high-amounts-ibuprofen.html

 

Many adults who use ibuprofen and other so-called nonsteroidal anti-inflammatory (NSAID) drugs take too much, increasing their risk of serious side effects like internal bleeding and heart attacks, a U.S. study suggests.

About 15 percent of adults taking ibuprofen (Motrin, Advil) or other NSAIDs like aspirin, naproxen (Aleve), celecoxib (Celebrex), meloxicam (Mobic) and diclofenac (Voltaren) exceeded the maximum recommended daily dose for these drugs, the study found.

“NSAIDs are among the most commonly used medicines in the U.S. and worldwide,” said lead study author Dr. David Kaufman of Boston University.

“These drugs can have serious side effects, including gastrointestinal bleeding and heart attacks, and are often taken without medical oversight because many products are available over-the-counter,” Kaufman said by email. “The attitude that users can choose their own dose regardless of label directions, along with poor knowledge of dosing limits, is associated with exceeding the daily limit.”

For the study, 1,326 people who reported taking ibuprofen in the previous month completed online medication diaries every day for one week.

All of the participants took ibuprofen during the diary week, and 87 percent of them only used over-the-counter, or nonprescription, versions, researchers report in Pharmacoepidemiology & Drug Safety.

Overall, 55 percent of participants took ibuprofen at least three days during the week, and 16 percent took it every day.

In addition to ibuprofen, 37 percent of the participants reported taking at least one other NSAID during the week, most often aspirin or naproxen. Less than half of them recognized that all of the products they were taking were NSAIDs.

One limitation of the study is that researchers only focused on recent and current ibuprofen users, which may not reflect what doses might be typical for sporadic or new users, the authors note.

Even so, the findings highlight a potential downside of making NSAIDs widely available without a prescription, said Dr. Gunnar Gislason, director of research for the Danish Heart Foundation in Cophenhagen.

“I believe that the message sent to the consumer when these drugs are widely available in convenience stores and gas stations is that these drugs are safe and you can use them safely for pain relief – thus no need for reading the label,” Gislason, who wasn’t involved in the study, said by email.

Even when people do read the label, they may still ignore it.

“If the recommended dosage does not give sufficient pain relief, it is easier to take more pills than seeking professional advice from a healthcare person or doctor,” Gislason added.

While doctors may prescribe NSAIDs for some muscle and joint disorders and certain other health problems, these drugs aren’t appropriate for many of the reasons that patients may buy them at the drugstore, said Dr. Liffert Vogt of the Academic Medical Center at the University of Amsterdam in the Netherlands.

“In my opinion NSAIDs should not be available as an over-the-counter drug, because of all their deleterious effects,” Vogt, who wasn’t involved in the study, said by email.

“For occasional use, acetaminophen (again in the right dose) is a much safer option and very efficacious as a pain killer,” Vogt added. “But we know that many people use NSAIDs for indications other than pain, such as flu, allergies, fever – and there is no medical base that indicates that NSAIDs or acetaminophen are of any use under these circumstances.”